lobular carcinoma in situ breast cancer

Release time ：Nov-11,2024

Lobular carcinoma in situ (LCIS) of the breast is an early form of breast cancer that typically does not pose an immediate threat to life. However, if untreated, it can progress to a more invasive form of cancer.

Therapy for LCIS often encompasses surgical intervention, occasionally in conjunction with radiotherapy or pharmacological treatments. The precise treatment strategy is tailored to the individual patient's circumstances and the physician's recommendations. Some patients may only require lumpectomy, while others might need a total mastectomy. Radiotherapy is generally administered postoperatively to minimize the risk of cancer recurrence. Hormone therapy may also be part of the treatment regimen to reduce the likelihood of relapse in hormone receptor-positive breast cancer.

For women diagnosed with LCIS, it is crucial to collaborate closely with their healthcare provider to devise a treatment plan that is most appropriate for their situation. Additionally, maintaining a healthy lifestyle, including a balanced diet, regular physical activity, and abstaining from smoking, can contribute to better therapeutic outcomes and reduce the risk of cancer recurrence.